Table 2.
Included studies.
| Author [Reference] | Year | Patients (n) | Gender (M/F) | Age (year) | Outcome |
Follow-up (months) | Local recurrence (LR) |
Metastatic disease (MD) |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANED | AWD | DOD | LR (n) | Time to LR (months) | MD (n) | Time to MD (months) | ||||||
| Sim et al. [1] | 1979 | 24 | 12/12 | 9–83; average 28 | 4 | 2 | 18 | 1–75; median 25.5 | 0 | N/A | 3 | 0–120; median 19 |
| Martin et al. [7] | 1982 | 6 | 1/5 | 6–31; median 15 | 4 | 0 | 2 | 0–120; median 22 | 0 | N/A | 1 | 13 |
| Giangaspero et al. [20] | 1984 | 1 | 0/1 | 8 | 1 | 0 | 0 | 24 | 0 | N/A | 1 | N/A |
| Roessner et al. [21] | 1985 | 1 | 0/1 | 29 | 0 | 0 | 1 | 204 | 1 | 192 | 1 | 168 |
| Ediken et al. [6] | 1987 | 13 | 5/8 | 6–28; median 15 | 5 | 3 | 5 | 2–84; median 20.5 | 0 | N/A | 4 | 6–24 |
| Sanjay et al. [22] | 1987 | 1 | 1/0 | 10 | 0 | 0 | 1 | 7 | 0 | N/A | 1 | 2 |
| Stea et al. [15] | 1988 | 8 | 2/6 | 6–31; median 17 | 3 | 1 | 4 | 10–216; median 57 | 1 | 60 | 5 | 9–120; median 22 |
| Ayala et al. [9] | 1989 | 27 | 12/15 | 6–28; median 14 | 12 | 1 | 14 | 1–115; median 20 | 0 | N/A | 17 | N/A |
| Bertoni et al. [8] | 1989 | 11 | 4/7 | 6–20; median 13 | 1 | 0 | 8 | 3–18; median 6 | 1 | 3 | 8 | 0–14; median 3 |
| Nguera et al. [23] | 1990 | 1 | 1/0 | 20 | 0 | 0 | 1 | 10 | 0 | N/A | 1 | 10 |
| Dickersin et al. [24] | 1991 | 4 | 3/1 | 17–39; median 25 | 0 | 2 | 2 | 4–78; median 12 | 0 | N/A | 1 | 72 |
| Huang et al. [25] | 1991 | 1 | 1/0 | 34 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Kyriakos et al. [26] | 1992 | 1 | 1/0 | 15 | 1 | 0 | 0 | 57 | 0 | N/A | 0 | N/A |
| Devaney et al. [27] | 1993 | 16 | N/A | 16–28; average 19 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stracca-Pansa et al. [28] | 1994 | 4 | 3/1 | 3–11; mean 7.5 | N/A | 1 | N/A | N/A | N/A | N/A | N/A | N/A |
| Park et al. [29] | 1995 | 1 | 0/1 | 8 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Robinson et al. [30] | 1995 | 1 | 0/1 | 30 | 1 | 0 | 0 | 9 | 0 | N/A | 0 | N/A |
| Nakajima et al. [11] | 1997 | 72 | 39/33 | 5–71; median 20 | 4 | 0 | 14 | 3–199 | 0 | N/A | 1 | 53 |
| Sipos et al. [31] | 1997 | 1 | 0/1 | 16 | 1 | 0 | 0 | 48 | 0 | N/A | 0 | N/A |
| Ye [32] | 1997 | 1 | 1/0 | 40 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tian et al. [33] | 1998 | 1 | 1/0 | 14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Lintz et al. [34] | 1999 | 1 | 1/0 | 32 | 0 | 0 | 1 | 36 | 0 | N/A | 1 | 0 |
| Mulligan et al. [35] | 1999 | 1 | 1/0 | 63 | 0 | 0 | 1 | 26 | 0 | N/A | 1 | 17 |
| Park et al. [36] | 1999 | 1 | 0/1 | 37 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Todesco et al. [37] | 2000 | 1 | 1/0 | 12 | 1 | 0 | 0 | 33 | 0 | N/A | 1 | 15 |
| Nakamura et al. [38] | 2001 | 1 | 1/0 | 36 | 1 | 0 | 0 | 95 | 0 | N/A | 1 | 48 |
| Cai et al. [39] | 2002 | 1 | 0/1 | 23 | 0 | 0 | 1 | 14 | 0 | N/A | 1 | N/A |
| Zhang et al. [40] | 2003 | 1 | 1/0 | 16 | 1 | 0 | 0 | 24 | 0 | N/A | 0 | 0 |
| Nishio et al. [41] | 2006 | 1 | 1/0 | 9 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Weng et al. [42] | 2006 | 1 | 1/0 | 18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Fang et al. [43] | 2009 | 1 | 1/0 | 24 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Li et al. [44] | 2009 | 1 | 0/1 | 32 | 1 | 0 | 0 | 12 | 0 | N/A | 0 | 0 |
| Kallel et al. [45] | 2009 | 1 | 1/0 | 14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Yang et al. [46] | 2009 | 1 | 1/0 | 31 | 1 | 0 | 0 | 24 | 0 | N/A | 0 | N/A |
| Bishop et al. [13] | 2010 | 5 | N/A | 11–37 | 1 | 1 | 2 | up to 48 | 1 | N/A | 1 | N/A |
| Machado et al. [14] | 2010 | 10 | 4/6 | 5–48; median 28 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| PosthumaDeBoer et al.[47] | 2010 | 1 | 1/0 | 30 | 1 | 0 | 0 | 6 | 0 | N/A | 1 | N/A |
| Qi et al. [48] | 2010 | 1 | 1/0 | 31 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debelenko et al. [49] | 2011 | 1 | 0/1 | 12 | 0 | 1 | 0 | 36 | 0 | N/A | 1 | 0 |
| Uma et al. [50] | 2011 | 1 | 0/1 | 28 | N/A | 1 | N/A | N/A | N/A | N/A | N/A | N/A |
| Ali et al. [51] | 2012 | 1 | 0/1 | 36 | 0 | 1 | 0 | 5 | 0 | N/A | 1 | 0 |
| Findik et al. [52] | 2012 | 1 | 0/1 | 28 | 1 | 0 | 0 | 17 | 0 | N/A | 0 | N/A |
| Futani et al. [53] | 2012 | 1 | 1/0 | 11 | 1 | 0 | 0 | 48 | 0 | N/A | 0 | N/A |
| Huang et al. [54] | 2012 | 14 | 7/7 | 12–73; median 29 | 1 | 1 | 1 | 12–15; median 15 | 1 | 12 | 0 | 0 |
| Jambhekar et al. [55] | 2012 | 1 | 0/1 | 17 | 0 | 1 | 0 | 9 | 0 | N/A | 1 | 5 |
| Pugi et al. [56] | 2012 | 1 | 1/0 | 11 | 1 | 0 | 0 | 12 | 0 | N/A | 0 | N/A |
| Kang et al. [57] | 2013 | 1 | 1/0 | 16 | 0 | 0 | 1 | 42 | 1 | 10 | 1 | 10 |
| Wan et al. [58] | 2013 | 12 | 6/6 | 11–59; median 27 | 3 | 3 | 0 | 4–55; median 15.5 | 1 | 4 | 0 | 0 |
| Sood et al. [59] | 2014 | 1 | 0/1 | 60 | 1 | 0 | 0 | 6 | 0 | N/A | 0 | N/A |
| Zhang et al. [60] | 2014 | 1 | 0/1 | 40 | 1 | 0 | 0 | 36 | 0 | N/A | 0 | N/A |
| Agarwal et al. [61] | 2015 | 1 | 0/1 | 16 | 0 | 0 | 1 | 6 | 0 | N/A | 0 | 0 |
| Handa et al. [62] | 2015 | 1 | 1/0 | 10 | 1 | 0 | 0 | 6 | 0 | N/A | 0 | N/A |
| Righi et al. [12] | 2015 | 36 | 17 | 7–72 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Chen et al. [63] | 2017 | 1 | 0/1 | 5 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Jeong et al. [64] | 2017 | 1 | 1/0 | 31 | 1 | 0 | 0 | 73 | 0 | N/A | 0 | N/A |
| Wang et al. [65] | 2017 | 32 | 16/16 | 13–76; median 30 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| AbdullGaffar [66] | 2018 | 1 | 0/1 | 32 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Syriac et al. [67] | 2019 | 1 | 0/1 | 36 | 0 | 1 | 0 | 96 | 0 | N/A | 1 | 96 |
| Current cases | N/A | 20 | 16/4 | 8–60; median 27 | 7 | 2 | 11 | 4–126; median 21 | 6 | 2–15; median 10.5 | 10 | 1–95; median 5.5 |
| Total | N/A | 356 | 170/165 | 5–83; median 17 | 62 | 22 | 89 | 1–216; median 20 | 13 | 2–192; median 10.5 | 66 | 0–168; median 10 |
Abbreviations: AWD, alive with disease; ANED, alive with no evidence of disease; DOD, died of disease; F, female; LR, local recurrence; M, male; MD, metastatic disease; N/A, not available.